Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRAX-944 open-label phase 2 study in adults with absence seizures
ACTRN12618000961246Phase 2Terminated
- Sponsor
- Praxis Precision Medicines
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ulixacaltamide in absence epilepsy and idiopathic epilepsy (IGE), sponsored by Praxis Precision Medicines. Primary endpoint: Safety and tolerability. Started Jan 2019; status: terminated.
02
Drugs
ulixacaltamide
03
Conditions
absence epilepsyidiopathic epilepsy (IGE)
Beyond the preview
Go deeper on ACTRN12618000961246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618000961246.